Press Release

Immunology Company argenx Announces $1.27 Billion Offering

Largest biotech primary follow-on to date
July 26, 2023

New York – July 26, 2023 – Cooley advised J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities and TD Cowen, representatives of the several underwriters, in the $1.27 billion follow-on offering by argenx SE, a global immunology company. Partners Rich Segal and Div Gupta, along with associate Darah Protas, led the Cooley team advising the underwriters.

On July 19, 2023, argenx announced full exercise of the underwriters’ option to purchase additional American depository shares (ADSs), bringing the total global offering gross proceeds to approximately $1.27 billion, from the sale of 2,581,633 ADSs at a price of $490 per ADS and the sale of 663,918 ordinary shares at a price of 436.37 euros per ordinary share. The offering closed on July 24, 2023.

Cooley has advised the underwriters on every public offering by argenx since its 2017 initial public offering, raising a total of $5.3 billion in gross proceeds.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.